The Problem: Best in class S-Phase cytotoxics can kill 100% of cells in the S-Phase. However, less than a third of cancer cells are in the S-Phase during chemotherapy.

The Opportunity: Boosting the number of cancer cells in the S-Phase from less than a third to an eventual goal of 100% would provide a market transforming technology. The drugs to do this already exist for the majority of cancers.

The Product: TS - CCSC protocols use tumor specific mutations, characteristics, and microenvironments to achieve tumor specific S-Phase enrichment and synchronization relative to successive administrations of S-phase cytotoxic chemotherapeutics, while simultaneously inhibiting tumor regrowth between administrations of S-Phase cytotoxic. The protocols use only FDA approved drugs, including drugs currently used in oncology and drugs repurposed from other areas of medicine. The TS-CCSC Protocol approach is a 3 step process that is repeated in cycles:

Overcoming Prior Art Failures: Prior art attempts at CCSC failed because of inadequate aggregation periods and lack of targeted aggregation. Our patents overcome these reasons for failure.

Cancers Targeted: The cancers targeted by our protocols are defined by mutation or characteristic modulated to achieve targeted S-Phase enrichment, rather than by the legacy categorization of cancers by the cell type from which they arose:

• HER1 Cancers (Patent Issued - US 7,507,704)
Cancers: ~ 55% NSCLC, ~ 50% glioblastomas (brain), ~50% pancreatic, ~ 15% breast, 54-74% cervical, 40-80% prostate, 35-70% ovarian, 80+% head & neck, 25-77% colorectal, 50-90% renal, 43-89% esophageal

• HER2 Cancers (Patent Issued - US 7,309,486)
Cancers: ~20% breast, 30% NSCLC (lung), ovarian

• Endocrine Dependent Cancers (Patent Issued - US 6,486,146)
Cancers: ~ 50% breast, prostate, uterine, ovarian

Return to Home Page

DISCLAIMER AND IMPORTANT NOTICE: The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments.

© 2009 Mark Zamoyski & NexGen Biomedical, Inc.